Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5807815 | 1.00 | HRH3 (0.48) | HRH3POLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL678884 | 0.97 | — | — | |
| SCHEMBL4087305 | 0.92 | — | — | |
| SCHEMBL4813915 | 0.85 | HRH3 (0.56) | HRH3POLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL7381950 | 0.83 | HRH3 (0.61) | HRH3POLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL678405 | 0.82 | HRH3 (0.52) | HRH3POLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL7281275 | 0.81 | HRH3 (0.65) | HRH3POLBMAPTALDH1A1CYP1A2 | |
| SCHEMBL10695726 | 0.81 | HRH3 (0.65) | HRH3POLBMAPTALDH1A1CYP1A2 | |
| SCHEMBL7382943 | 0.81 | HRH3 (0.65) | HRH3POLBMAPTALDH1A1CYP1A2 | |
| SCHEMBL7282473 | 0.81 | HRH3 (0.65) | HRH3POLBMAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | claimed |
| US-7932264-B2 | Sinomenine derivatives and preparation and uses thereof | NATUREMED GROUP CORPORATION (US) | 2011-04-26 | — | — | US | claimed |
| EP-0827507-B1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM CA LTD (CA) | 1999-06-16 | — | — | EP | claimed |
| EP-0827507-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-03-11 | — | — | EP | claimed |
| WO-1996031527-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1996-10-10 | — | — | WO | claimed |
| US-5545640-A | VIRICIDES, HIV; AIDS | BIO-MEGA/BOEHRINGER INGELEHEIM RESEARCH INC. (CA) | 1996-08-13 | — | — | US | claimed |
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-03-10 | — | — | US | disclosed |
| EP-3558999-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2019-10-30 | — | — | EP | disclosed |
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| US-10053467-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-21 | — | — | US | disclosed |
| WO-2018115383-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-28 | — | — | WO | disclosed |
| US-4246284-A | Aminosulfonyl-substituted aryloxyalkyl diketones | STERLING DRUG INC. (US) | 1981-01-20 | — | — | US | disclosed |
| US-4198436-A | Dialkylamino- and dialkylaminoalkoxy-substituted aryloxyalkyl diketones | STERLING DRUG INC. (US) | 1980-04-15 | — | — | US | disclosed |
| US-4182727-A | 4-[6-(4-Cyanophenoxy)hexyl]-3,5-heptanedione | STERLING DRUG INC. (US) | 1980-01-08 | — | — | US | disclosed |
| US-4182761-A | Acyloxy-substituted aryloxyalkyl diketones | STERLING DRUG INC. (US) | 1980-01-08 | — | — | US | disclosed |
| US-4171376-A | Aryloxyalkyl keto-esters | STERLING DRUG INC. (US) | 1979-10-16 | — | — | US | disclosed |
| US-4133959-A | Aryloxyalkyl diketones | STERLING DRUG INC. (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053467-B2 | Therapeutic isoxazole compounds | MAOB, MAOA, XDH | HRH3 926/4885POLB 941/4885MAPT 935/4885 |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | SGMS2, PHOSPHO1, SGMS1 | HRH3 2658/4885POLB 3983/4885MAPT 2107/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | HRH3 1216/4885POLB 4595/4885MAPT 2813/4885 |
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | HRH3 668/4885POLB 1612/4885MAPT 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.